

**REMARKS**

Claims 1-5 are pending after entry of the amendments set forth herein.

Claim 1 is amended. Support for the amendment is found in the claims as originally filed, and throughout the specification, in particular at the following exemplary locations: paragraph 41 on pages 11 and 12. Accordingly, no new matter is added by these amendments.

Claims 6-23 are canceled without prejudice to renewal. Applicants expressly reserve the right to pursue any canceled subject matter in one or more continuation and/or divisional applications.

**Response to Restriction Requirement**

In the Restriction Requirement, the Examiner required election of one of the following groups of claims:

Group I: claims 1-5, drawn to a method for detecting a cancerous colon cell;

Group II: claims 6-8, drawn to assessing the cancerous phenotype of a colon cell;

Group III: claims 9-12 and 23, drawn to a method for suppressing or inhibiting a cancerous phenotype of a cancerous cell;

Group IV: claim 13, drawn to a method of assessing the tumor burden of a subject;

Group V: claims 14-18, drawn to a method for identifying a gene product as a target for a cancer therapeutic; and,

Group IV: claims 19-22, drawn to a method for identifying agents that decrease biological activity of a gene product.

**Applicants hereby elect to prosecute the claims of Group I, without traverse.**

The Restriction Requirement also required that the Applicants elect a sequence.

**Applicants hereby elect to prosecute SEQ ID NO: 498.**

The Restriction Requirement also required that the Applicants elect either nucleic acid or polypeptide as a gene product, for initial examination.

**Applicants hereby elect to prosecute nucleic acid as a gene product.** Claim 1 is generic, and claims 1, 2, 4 and 5 read on nucleic acid gene products.

Applicants respectfully request rejoinder of withdrawn species claims upon allowance of a claim that encompasses the currently withdrawn species.

Applicants expressly reserve the right under 35 USC §121 to file one or more divisional applications directed to the non-elected subject matter during the pendency of this application.

**CONCLUSION**

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number 2300-16336.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: January 9, 2004

By: 

James S. Keddie, Ph.D.  
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

F:\DOCUMENT\2300\16336\Response to restriction requirement dated July 9, 2003.doc